NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of diagnostics and lab services industry veteran ...

NeoGenomics has seen a strong start to the year. The Fort Myers-based cancer testing and research lab reported revenue growth of 8% in the first quarter over the year. Revenue rose from roughly $156.2 ...

FORT MYERS, FL / ACCESSWIRE / December 28, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced that NeoGenomics Laboratories, Inc., a ...

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q4 CY2025 results exceeding the market’s revenue ...

NeoGenomics reported mixed results for the second quarter. The Fort Myers-based cancer testing and research lab announced revenue growth of more than 10%, compared to the same quarter last year.

NeoGenomics (NEO) moving toward a full U.S. clinical launch of its RaDaR ST molecular residual disease (MRD) assay in Q1 2026 FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ:NEO), a ...

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on NeoGenomics (NASDAQ:NEO) in the last three months. The table below offers a condensed view of ...

Southwest Florida companies Hertz, Herc, NeoGenomics, and Alico report Q4 and full-year 2025 earnings, showing mixed results.